863 related articles for article (PubMed ID: 16291982)
21. The metabolic basis of atherogenic dyslipidemia.
Vinik AI
Clin Cornerstone; 2005; 7(2-3):27-35. PubMed ID: 16473258
[TBL] [Abstract][Full Text] [Related]
22. Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors.
Cox SL
Drugs Today (Barc); 2005 Aug; 41(8):499-508. PubMed ID: 16234873
[TBL] [Abstract][Full Text] [Related]
23. [Medication of the month. Rimonabant (Acomplia): first CB1 receptor antagonist of the endocannabinoid system].
Scheen AJ; Van Gaal LF
Rev Med Liege; 2008 Jan; 63(1):50-5. PubMed ID: 18303686
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia.
Florentin M; Kostapanos MS; Nakou ES; Elisaf M; Liberopoulos EN
J Cardiovasc Pharmacol Ther; 2009 Dec; 14(4):274-82. PubMed ID: 19724023
[TBL] [Abstract][Full Text] [Related]
25. ADAGIO-Lipids gives promises but faces the setbacks.
Taskinen MR
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):339-40. PubMed ID: 19228609
[No Abstract] [Full Text] [Related]
26. CB(1) blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans.
Bergholm R; Sevastianova K; Santos A; Kotronen A; Urjansson M; Hakkarainen A; Lundbom J; Tiikkainen M; Rissanen A; Lundbom N; Yki-Järvinen H
Int J Obes (Lond); 2013 May; 37(5):699-703. PubMed ID: 22828945
[TBL] [Abstract][Full Text] [Related]
27. Rimonabant.
Henness S; Robinson DM; Lyseng-Williamson KA
Drugs; 2006; 66(16):2109-19; discussion 2120-1. PubMed ID: 17112304
[TBL] [Abstract][Full Text] [Related]
28. Pleiotropic effects of rimonabant: clinical implications.
Després JP
Curr Pharm Des; 2009; 15(5):553-70. PubMed ID: 19199981
[TBL] [Abstract][Full Text] [Related]
29. [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
Boekholdt SM; Jukema JW; Peters RJ
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2615-9. PubMed ID: 18161262
[TBL] [Abstract][Full Text] [Related]
30. Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity.
Patel PN; Pathak R
Am J Health Syst Pharm; 2007 Mar; 64(5):481-9. PubMed ID: 17322160
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular disease under the influence of excess visceral fat.
Després JP
Crit Pathw Cardiol; 2007 Jun; 6(2):51-9. PubMed ID: 17667865
[TBL] [Abstract][Full Text] [Related]
32. What is the potential role of cannabinoid-1 receptor blockade in glucose and lipid management?
Jensen MD
Am J Med; 2007 Sep; 120(9 Suppl 1):S25-31; discussion S31-2. PubMed ID: 17720358
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.
Christensen R; Kristensen PK; Bartels EM; Bliddal H; Astrup A
Lancet; 2007 Nov; 370(9600):1706-13. PubMed ID: 18022033
[TBL] [Abstract][Full Text] [Related]
34. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats.
Janiak P; Poirier B; Bidouard JP; Cadrouvele C; Pierre F; Gouraud L; Barbosa I; Dedio J; Maffrand JP; Le Fur G; O'Connor S; Herbert JM
Kidney Int; 2007 Dec; 72(11):1345-57. PubMed ID: 17882151
[TBL] [Abstract][Full Text] [Related]
35. [The endocannabinoid system and treatment of obesity].
Aronsen L
Tidsskr Nor Laegeforen; 2008 Feb; 128(5):570-1. PubMed ID: 18311201
[TBL] [Abstract][Full Text] [Related]
36. Novel therapies for cardiometabolic risk reduction and implications for clinical practice.
Watson KE
Rev Cardiovasc Med; 2007; 8 Suppl 4():S37-42. PubMed ID: 17934393
[TBL] [Abstract][Full Text] [Related]
37. The endocannabinoid system and cardiometabolic risk: effects of CB1 receptor blockade on lipid metabolism.
Deedwania P
Int J Cardiol; 2009 Jan; 131(3):305-12. PubMed ID: 18715660
[TBL] [Abstract][Full Text] [Related]
38. The role of endocannabinoid system blockade in the treatment of the metabolic syndrome.
Kakafika AI; Mikhailidis DP; Karagiannis A; Athyros VG
J Clin Pharmacol; 2007 May; 47(5):642-52. PubMed ID: 17392496
[TBL] [Abstract][Full Text] [Related]
39. Rimonabant: endocannabinoid inhibition for the metabolic syndrome.
Wierzbicki AS
Int J Clin Pract; 2006 Dec; 60(12):1697-706. PubMed ID: 17109677
[TBL] [Abstract][Full Text] [Related]
40. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia.
Dujovne CA; Zavoral JH; Rowe E; Mendel CM;
Am Heart J; 2001 Sep; 142(3):489-97. PubMed ID: 11526363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
